Learn more aboutThe Science
OMass is a world-leader in native mass spectrometry that allows protein targets to be studied in a folded native-like state thereby preserving any associated non-covalent interactions. This allows drug interactions to be captured as well as the influence of those drugs on downstream interaction networks that are necessary for dictating function. In this way, the technology delivers superior resolution to traditional pharmacology assays enabling a clearer, more detailed picture of how a putative ligand engages a protein target with function evaluated in parallel. The additional information obtained in the OMass assays can reveal new biology even at well-studied receptors and the cell-free system is unbiased for different ligand chemistries unmasking chemical space of high therapeutic potential inaccessible to cell-based assays.
The platform is based on work initiated by our scientific founders in the laboratory of Professor Carol Robinson at Oxford University and is currently being applied to G-protein coupled receptors and other membrane proteins where we have developed a portfolio of intellectual property protection. We are optimizing and automating our approach and this is part-funded by an Innovate Grant, awarded in March 2018.
We have initiated programs against three high impact G-protein coupled receptor targets (GPCRs) with a focus on genetically defined patient populations and/or immunological dysfunction. We are actively evaluating additional GPCRs and solute carriers aligned with our focus on immunology and genetic disease